Baker Bros. Advisors LP bought $21M of BCYC
director, owner at BICYCLE THERAPEUTICS PLC. 1,485,397 shares at an average of $14.29, traded Dec 13, 2024, filed Dec 17, 2024.
Score components
- +15RoleDirector
- +25Trade size$21.2M at market
- +10Relative to holdingsHoldings up 189%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-137446, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 13, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +2,809 | $13.50 | $38k | 790,763 | Dec 17, 2024 |
| Dec 13, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +30,241 | $13.50 | $408k | 8,666,247 | Dec 17, 2024 |
| Dec 13, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +5,573 | $13.63 | $76k | 796,336 | Dec 17, 2024 |
| Dec 13, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +59,995 | $13.63 | $818k | 8,726,242 | Dec 17, 2024 |
| Dec 13, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +22,722 | $13.72 | $312k | 819,058 | Dec 17, 2024 |
| Dec 13, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +244,587 | $13.72 | $3.4M | 8,970,829 | Dec 17, 2024 |
| Dec 13, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +52,656 | $13.80 | $727k | 871,714 | Dec 17, 2024 |
| Dec 13, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +566,814 | $13.80 | $7.8M | 9,537,643 | Dec 17, 2024 |
| Dec 16, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +42,369 | $15.34 | $650k | 914,083 | Dec 17, 2024 |
| Dec 16, 2024 | POpen-market purchase American Depositary Sharesindirect: See Footnotes | +457,631 | $15.34 | $7.0M | 9,995,274 | Dec 17, 2024 |
Related signals
Other insiders at BICYCLE THERAPEUTICS PLC and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 38Weak | sell 8 | BCYC BICYCLE THERAPEUTICS PLC | Santiago Arroyo CHIEF DEVELOPMENT OFFICER | $70k | 4,943 | |
| 51Moderate | sell 8 | BCYC BICYCLE THERAPEUTICS PLC | Kevin Lee CHIEF EXECUTIVE OFFICER | $173k | 12,130 | |
| 35Weak | sell 8 | BCYC BICYCLE THERAPEUTICS PLC | Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | $30k | 2,118 | |
| 37Weak | sell 8 | BCYC BICYCLE THERAPEUTICS PLC | Michael Skynner CHIEF TECHNOLOGY OFFICER | $60k | 4,223 | |
| 44Moderate | sell 8 | BCYC BICYCLE THERAPEUTICS PLC | Alistair Milnes CHIEF OPERATING OFFICER | $78k | 5,514 | |
| 37Weak | sell 8 | BCYC BICYCLE THERAPEUTICS PLC | Nigel Crockett CHIEF BUSINESS OFFICER | $50k | 3,519 | |
| 37Weak | sell 8 | BCYC BICYCLE THERAPEUTICS PLC | Alethia Young Chief Financial Officer | $20k | 1,395 | |
| 23Weak | sell 810b5-1 | BCYC BICYCLE THERAPEUTICS PLC | Travis Alvin Thompson CHIEF ACCOUNTING OFFICER | $67k | 4,595 | |
| 1Weak | sell10b5-1 | BCYC BICYCLE THERAPEUTICS PLC | Travis Alvin Thompson CHIEF ACCOUNTING OFFICER | $157k | 6,256 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.